Abstract

BackgroundPosterior reversible encephalopathy syndrome (PRES) is usually a benign, yet underdiagnosed clinical condition associated with subacute to acute neurological manifestations primarily affecting white matter. PRES is reversible when recognized promptly and treated early by removal of the insulting factor; however, can lead to irreversible and life-threatening complications such as cerebral hemorrhage, cerebellar herniation, and refractory status epilepticus.MethodsWe utilized the National Inpatient Sample database provided by the Healthcare Cost and Utilization Project (HCUP-NIS) 2017 to investigate the demographic variables (age, sex, and race) for patients with PRES, concomitant comorbidities and conditions, inpatient complications, inpatient mortality, length of stay (LOS), and disposition.ResultsA total of 635 admissions for patients aged 18 years or older with PRES were identified. The mean age was 57.2 ± 0.6 years old with most encounters for female patients (71.7%, n = 455) and white as the most prevalent race. Half the patients in our study presented with seizures (50.1%, n = 318), sixty-three patients (9.9%) presented with vision loss, and sixty-four patients (10.1%) had speech difficulty. In addition, 45.5% of patients had hypertensive crisis (n = 289). 2.2% of hospitalizations had death as the outcome (n = 14). The mean LOS was 8.2 (±0.3) days, and the mean total charges were $92,503 (±$5758). Inpatient mortality differed between males and females (1.7% vs. 2.4%) and by race (3.6% in black vs. 1.8% in white) but was ultimately determined to be not statistically significant. Most patients who present with vision disturbance have a high risk of intracranial hemorrhage. Furthermore, end-stage renal disease, atrial fibrillation, and malignancy seemed to be linked with a very high risk of mortality.ConclusionPRES, formerly known as reversible posterior leukoencephalopathy, is a neurological disorder with variable presenting symptoms. Although it is generally a reversible condition, some patients suffer significant morbidity and even mortality. To the best of our knowledge, this is the largest retrospective cohort of PRES admissions that raises clinician awareness of clinical characteristics and outcomes of this syndrome.

Highlights

  • Posterior reversible encephalopathy syndrome (PRES) is a clinical, radiographic syndrome ranging from subacute to acute neurological manifestations primarily affecting the white matter [1, 2]

  • At present, the exact pathophysiology of PRES unknown; multiple theories have centered around the disruption of the blood-brain barrier (BBB) by an insulting factor leading to extravasation of intravascular fluid and cerebral edema [9]

  • Our study revealed a strong correlation between vision loss, among all other presentations, with intracranial hemorrhage

Read more

Summary

Introduction

Posterior reversible encephalopathy syndrome (PRES) is a clinical, radiographic syndrome ranging from subacute to acute neurological manifestations primarily affecting the white matter [1, 2]. PRES has been associated with hypertension, eclampsia, chemotherapeutic and immunosuppression medications, and transplant-recipient patients [1, 2] It is considered a benign disease if recognized early and promptly treated with the removal of causative factors [3, 4]. PRES is still an underdiagnosed neurological syndrome with a constellation of symptoms that share characteristic neuroimaging findings [2, 3]. It commonly affects middle-aged females with no statistical significance in mortality, gender, or race [5]. Posterior reversible encephalopathy syndrome (PRES) is usually a benign, yet underdiagnosed clinical condition associated with subacute to acute neurological manifestations primarily affecting white matter. PRES is reversible when recognized promptly and treated early by removal of the insulting factor; can lead to irreversible and life-threatening complications such as cerebral hemorrhage, cerebellar herniation, and refractory status epilepticus

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call